Kyle J. Norton
Prostate Cancer is a medical condition characterized by irregular cell growth and multiplied disorderly in the prostate tissues.
Beet, best known as the beetroot or garden beet, belonging to the amaranth family, is a perennial plant with leafy stems growing to 1–2 m tall.
Red beetroot (Beta vulgaris L.) may have a profound effect in reduced risk and treatment of prostate cancer, some studies suggested.
According to the Howard University, red beetroot (Beta vulgaris L.) extract (B), approved by Food and Drug Administration and European Union, in drinking water may be safe and used as cancer chemopreventive effect in humans.
Intake of the extract showed a significant effect in reduced synergistic antiproliferative activity against prostate (PC-3) tumor cells of human origin.
When combined anticancer drug doxorubicin (D), the combination acted synergistically in the expression of cytotoxicity against prostate cancer at a ratio of 1:5.
In a total of 24 patients (mean age 68+/-8 years) with hormone-resistant and metastatic prostate cancer treated with taxan chemotherapy, given twice 10 g daily for 1 month of natural table beet products come from commercial service, intake of beet juice showed a significant effect in control of the progression of prostate cancer in promoted life expectancy and reduced toxicity side effect induced by conventional chemo-drug.
The efficacy may be contributed by the mediated activities of phytochemicals in the juice in the inhibition of inflammation through the expression of the production of antioxidants.
The study also suggested that moderate and permanent consumption of table beet products may favorably affect the life expectancy of prostate cancer patients.
Furthermore, in the testing extract of red beetroot (Beta vulgaris L.), the FDA-approved red food color E162, against various cancer cell lines, researchers at Howard University found that the extract showed significant cytotoxicity in decreased the growth rate of the PC-3 cells, although lesser in compared to doxorubicin, a chemo medicine( (8.6% vs. 100%, respectively, at 29 µg/ml concentration of each, three-day test period).
The study also suggested that betanin, the major betacyanin constituent found in beetroot, may be phytochemicals responsible for the cytotoxicity.
These findings showed that beetroot may be used as a functional food to a reduced risk of early-onset and treatment of prostate cancer. And reduced adverse toxicity when used in combination with chemo drugs.
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
Back to Kyle J. Norton's Home page http://kylejnorton.blogspot.ca
Author Biography
Kyle J. Norton(Scholar, Master of Nutrients), all right reserved.
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, healthblogs, self-growth, best before it's news, the Karate GB Daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as the international journal Pharma and Bio Science, ISSN 0975-6299.
Sources
(1) Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines by Kapadia GJ1, Rao GS, Ramachandran C, Iida A, Suzuki N, Tokuda H.(PubMed)
(2) [Effects of bioactive molecules of Beta vulgaris L. ssp. esculenta var. rubra on metastatic prostate cancer].[Article in Hungarian]by Nyirády P1, Sárdi E, Beko G, Szucs M, Horváth A, Székely E, Szentmihályi K, Romics I, Blázovics A.(PubMed)
(3) Cytotoxic effect of the red beetroot (Beta vulgaris L.) extract compared to doxorubicin (Adriamycin) in the human prostate (PC-3) and breast (MCF-7) cancer cell lines by Kapadia GJ1, Azuine MA, Rao GS, Arai T, Iida A, Tokuda H.(PubMed)
No comments:
Post a Comment